Lilly enters CIA as part of $1.4 billion settlement

Share this article:

As part of its $1.415 billion settlement for off-label marketing of Zyprexa, Eli Lilly & Co. will enter a Corporate Integrity Agreement with the HHS Office of Inspector General.

The agreement requires that Lilly: send doctors letters advising them of the settlement and giving them a means of reporting questionable conduct by sales reps; list payments to doctors on its website; and that its board and senior management regularly certify that the company is in compliance and has an effective program to stay that way.

As part of its $62 million October settlement with 32 states and the District of Columbia, Lilly agreed to furnish those state's attorney generals with a list of all healthcare professionals paid more than $100 for promotional speaking and consulting in the US. Lilly had previously announced that it would report payments to physicians of over $500 as part of a transparency initiative.

Lilly's agreement with the states, binding until 2014, includes provisions governing promotional activities, dissemination of medical information, CME grants, payments to consultants and speakers, sampling and clinical research and stipulates areas and activities which are off-limits to Lilly sales and marketing teams.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...